AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Amgen (AMGN) Q4 earnings and revenue beat estimates
February 6, 2024 4:14 PM ESTAmgen (NASDAQ: AMGN) posted better-than-expected fourth-quarter earnings and revenue.
The biopharma company reported Q4 earnings per share (EPS) of $4.71, topping the consensus projection of $4.59. It generated $8.2 billion in revenue during the quarter, up 20% year-over-year, and above the estimated $8.12 billion.
Product sales brought in... More
Amgen (AMGN) Tops Q4 EPS by 12c, Offers Guidance
February 6, 2024 4:03 PM ESTAmgen (NASDAQ: AMGN) reported Q4 EPS of $4.71, $0.12 better than the analyst estimate of $4.59. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.12 billion.
GUIDANCE:
Amgen sees FY2024 EPS of $18.90-$20.30, versus the consensus of $19.83. Amgen sees... More
